PE20071055A1 - Anticuerpos anti mn - Google Patents
Anticuerpos anti mnInfo
- Publication number
- PE20071055A1 PE20071055A1 PE2006001590A PE2006001590A PE20071055A1 PE 20071055 A1 PE20071055 A1 PE 20071055A1 PE 2006001590 A PE2006001590 A PE 2006001590A PE 2006001590 A PE2006001590 A PE 2006001590A PE 20071055 A1 PE20071055 A1 PE 20071055A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- sequence
- identity
- amino acid
- acid sequence
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
REFERIDA A UN ANTICUERPO O FRAGMENTO DE ANTICUERPO QUE TIENE UN SITIO DE UNION AL ANTIGENO ESPECIFICAMENTE DIRIGIDO CONTRA UNA PROTEINA MN, DONDE EL SITIO DE UNION AL ANTIGENO INCLUYE AL MENOS UNA CDR1, CDR2 O CDR3, DONDE a) DICHA CDR1 SE SELECCIONA DEL GRUPO FORMADO POR NUMEROS DE ID DE SEC: 57, 58, 59, 60, 61, 62, 77, 80, 81, 86, 87, 88, 89, 98, 99, 104, 107, 108 Y UNA SECUENCIA DE AMINOACIDOS QUE TIENE MAS DE 80% DE IDENTIDAD DE SECUENCIA DE AMINOACIDOS CON CUALQUIERA DE NUM. DE ID DE SEC: 57, 58, 59, 60, 61, 62, 77, 80, 81, 86, 87, 88, 89, 98, 99, 104, 107 O 108, b) DICHA CDR2 SE SELECCIONA DEL GRUPO DE NUM. DE ID DE SEC: 63,64, 65, 66, 67, 68, 69, 78, 82, 83, 90, 91, 92, 93, 100, 101, 105, 109, 110 Y UNA SECUENCIA DE AMINOACIDOS QUE TIENE MAS DE 80% DE IDENTIDAD DE SECUENCIA CON CUALQUIERA DE NUM. DE ID DE SEC: 63,64, 65, 66, 67, 68, 69, 78, 82, 83, 90, 91, 92, 93, 100, 101, 105, 109 O 110, c) DICHA CDR3 SE SELECCIONA DEL GRUPO FORMADO POR NUM. DE ID DE SEC: 70, 71, 72, 73, 74, 75, 76, 79, 84, 85, 94, 95, 96, 97, 102, 103, 106, 111, 112 Y Y UNA SECUENCIA DE AMINOACIDOS QUE TIENE MAS DE 80% DE IDENTIDAD DE SECUENCIA CON CUALQUIERA DE NUM. DE ID DE SEC: 70, 71, 72, 73, 74, 75, 76, 79, 84, 85, 94, 95, 96, 97, 102, 103, 106, 111, 112. DICHOS ANTIGENOS SON ESPECIFICOS PARA PROTEINAS MN Y SON UTILES EN EL TRATAMIENTO DE CANCERES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74971605P | 2005-12-12 | 2005-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20071055A1 true PE20071055A1 (es) | 2007-12-22 |
Family
ID=38163479
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001590A PE20071055A1 (es) | 2005-12-12 | 2006-12-12 | Anticuerpos anti mn |
PE2011000458A PE20110797A1 (es) | 2005-12-12 | 2006-12-12 | Anticuerpos anti mn |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011000458A PE20110797A1 (es) | 2005-12-12 | 2006-12-12 | Anticuerpos anti mn |
Country Status (28)
Country | Link |
---|---|
US (2) | US8168758B2 (es) |
EP (2) | EP1963372B1 (es) |
JP (2) | JP2009519341A (es) |
KR (1) | KR101551878B1 (es) |
CN (2) | CN102585001B (es) |
AR (1) | AR058325A1 (es) |
AU (1) | AU2006326476A1 (es) |
BR (1) | BRPI0619606A2 (es) |
CA (1) | CA2633038A1 (es) |
CR (1) | CR10068A (es) |
DO (1) | DOP2006000277A (es) |
EC (1) | ECSP088529A (es) |
ES (1) | ES2428373T3 (es) |
GT (1) | GT200800098A (es) |
HK (2) | HK1133441A1 (es) |
HN (1) | HN2008000878A (es) |
IL (1) | IL192129A0 (es) |
MA (1) | MA30684B1 (es) |
MX (1) | MX2008007502A (es) |
NZ (1) | NZ569698A (es) |
PE (2) | PE20071055A1 (es) |
RU (2) | RU2427590C2 (es) |
SG (1) | SG170793A1 (es) |
TN (1) | TNSN08255A1 (es) |
TW (2) | TW201323443A (es) |
UY (1) | UY30006A1 (es) |
WO (1) | WO2007070538A2 (es) |
ZA (1) | ZA200805741B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE516818T1 (de) | 2002-07-31 | 2011-08-15 | Seattle Genetics Inc | Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
NZ583367A (en) | 2007-07-16 | 2012-10-26 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
CN101802013B (zh) | 2007-07-16 | 2014-07-02 | 健泰科生物技术公司 | 人源化抗cd79b抗体和免疫偶联物及使用方法 |
AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
MX2010008437A (es) | 2008-01-31 | 2010-11-25 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso. |
TWI506037B (zh) | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | 捲曲結合劑類及彼等之用途 |
US20140024050A1 (en) * | 2009-03-10 | 2014-01-23 | Abbott Laboratories | Antibodies which detect pivkaii and methods of use thereof |
HUE029619T4 (en) | 2009-03-10 | 2017-07-28 | Biogen Ma Inc | Anti-bcma antibodies |
JP5774595B2 (ja) | 2009-10-28 | 2015-09-09 | ヤンセン バイオテツク,インコーポレーテツド | 抗glp−1r抗体及びそれらの使用 |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
JP2011206049A (ja) | 2010-03-08 | 2011-10-20 | Sumio Sugano | 壊死マーカー及びその用途 |
CN102971337B (zh) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
CA2833477A1 (en) | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
CA2859255A1 (en) | 2011-12-14 | 2013-06-20 | Seattle Genetics, Inc. | New antibody drug conjugates (adcs) and the use thereof |
ES2728278T3 (es) | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
EP2950885B1 (en) | 2013-02-04 | 2018-11-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
US8975290B2 (en) * | 2013-03-01 | 2015-03-10 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
EP3039042A1 (en) * | 2013-08-29 | 2016-07-06 | University of Copenhagen | Anti-adam12 antibodies for the treatment of cancer |
BR112016014830A2 (pt) | 2013-12-23 | 2017-09-19 | Bayer Pharma AG | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp |
LT3262071T (lt) | 2014-09-23 | 2020-06-25 | F. Hoffmann-La Roche Ag | Anti-cd79b imunokonjugatų naudojimo būdai |
JP6743015B2 (ja) | 2014-12-15 | 2020-08-19 | バイエル ファーマ アクチエンゲゼルシャフト | Ksp阻害剤の脱グリコシル化抗tweakr抗体との抗体薬物複合体(adc類) |
SG10201908685QA (en) | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
US20180318438A1 (en) | 2015-06-23 | 2018-11-08 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies |
JP6905941B2 (ja) | 2015-06-23 | 2021-07-21 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質(ksp)阻害剤の抗b7h3抗体との抗体薬物複合体 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
PE20181852A1 (es) | 2016-03-24 | 2018-12-03 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles |
US11001636B2 (en) | 2016-06-15 | 2021-05-11 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies |
US20190351066A1 (en) | 2016-12-21 | 2019-11-21 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
CA3047489A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) having enzymatically cleavable groups |
CA3047522A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
EP3746079A1 (en) | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
CN112601553A (zh) | 2018-06-18 | 2021-04-02 | 拜耳股份有限公司 | 具有可酶切的接头和改善的活性谱的针对cxcr5的结合剂-药物缀合物 |
MX2021005686A (es) | 2018-11-14 | 2021-07-07 | Bayer Ag | Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer. |
US20220089721A1 (en) | 2018-12-19 | 2022-03-24 | Bayer Aktiengesellschaft | Pharmaceutical combination of anti ceacam6 and tim3 antibodies |
WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
CA3164037A1 (en) | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
CN115335082A (zh) * | 2020-03-27 | 2022-11-11 | 光爱科技公司 | 用于杀死肿瘤细胞的医药品 |
EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
CN113281513A (zh) * | 2021-05-17 | 2021-08-20 | 上海执诚生物科技有限公司 | 一种mmp-3试剂盒及其制备方法和应用 |
CN116444653B (zh) * | 2023-03-09 | 2024-03-15 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US564830A (en) | 1896-07-28 | Sprocket-chain and wheel | ||
US1399790A (en) | 1919-09-25 | 1921-12-13 | James J Phillips | Winding means for spring-motors |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4454106A (en) | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US4745181A (en) | 1986-10-06 | 1988-05-17 | Ciba Corning Diagnostics Corp. | Polysubstituted aryl acridinium esters |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
ATE175118T1 (de) | 1990-10-05 | 1999-01-15 | Medarex Inc | Gezielte immunostimulierung mit bispezifischen stoffen |
EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
US5773280A (en) | 1992-03-20 | 1998-06-30 | The Board Of Trustees Of The University Of Illinois | Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses |
IE921342A1 (en) | 1991-04-26 | 1992-11-04 | Surface Active Ltd | Novel antibodies, and methods for their use |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US5407653A (en) | 1991-06-26 | 1995-04-18 | Brigham And Women's Hospital | Evaluation of the multidrug resistance phenotype |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US6004554A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US6297041B1 (en) | 1992-03-11 | 2001-10-02 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
US5387676A (en) | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
US5395752A (en) | 1993-03-19 | 1995-03-07 | Ciba Corning Diagnostics Corp. | Long emission wavelength chemiluminescent compounds and their use in test assays |
WO1996013583A2 (en) | 1994-10-20 | 1996-05-09 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Targeted hetero-association of recombinant proteins to multi-functional complexes |
ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
US6828422B1 (en) | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
CN100335501C (zh) | 1996-09-26 | 2007-09-05 | 中外制药株式会社 | 抗人副甲状腺激素相关蛋白的抗体 |
SE9700384D0 (sv) | 1997-02-04 | 1997-02-04 | Biacore Ab | Analytical method and apparatus |
IL132896A0 (en) | 1997-05-15 | 2001-03-19 | Chugai Pharmaceutical Co Ltd | Cachexia remedy |
JP2002501721A (ja) | 1997-08-01 | 2002-01-22 | モルフォシス・アクチェンゲゼルシャフト | 多量体(ポリ)ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ |
AU753336B2 (en) | 1997-11-10 | 2002-10-17 | G.D. Searle & Co. | Use of alkylated iminosugars to treat multidrug resistance |
US6200814B1 (en) | 1998-01-20 | 2001-03-13 | Biacore Ab | Method and device for laminar flow on a sensing surface |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
DE60044997D1 (de) | 1999-07-02 | 2010-11-04 | Morphosys Ag | Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden |
JP4312403B2 (ja) | 1999-07-20 | 2009-08-12 | モルフォシス・アクチェンゲゼルシャフト | (ポリ)ペプチド/タンパク質を、ジスルフィド結合を介してバクテリオファージ粒子に表示させる新規方法 |
IT1307309B1 (it) | 1999-12-30 | 2001-10-30 | Enea Ente Nuove Tec | Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono. |
ATE337395T1 (de) * | 2001-02-07 | 2006-09-15 | Wilex Ag | Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
AR036833A1 (es) * | 2001-10-18 | 2004-10-06 | Bayer Corp | Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular. |
AU2002351208A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen |
AU2002359130A1 (en) | 2001-12-21 | 2003-07-15 | Biacore Ab | Immobilization of binding agents |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
AU2003223186A1 (en) * | 2002-05-23 | 2004-01-23 | Bayer Healthcare | SOLUBLE FORM OF CARBONIC ANHYDRASE IX (s-CA IX), ASSAYS TO DETECT s-CA IX AND CA IX's COEXPRESSION WITH HER-2/neu/c-erbB-2 |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
EP1576010A4 (en) * | 2002-08-23 | 2006-12-27 | Chiron Corp | THERAPEUTIC COMPOSITIONS AND METHODS FOR CANCER CHARACTERIZED BY EXPRESSION OF MN / CA IX ANTIGEN ASSOCIATED WITH TUMORS |
JP2004170195A (ja) | 2002-11-19 | 2004-06-17 | Reverse Proteomics Research Institute Co Ltd | タンパク質の固定化方法 |
AU2004260936B2 (en) * | 2003-06-27 | 2010-06-10 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
CN1281753C (zh) * | 2003-12-08 | 2006-10-25 | 陈志南 | 抗人大肠癌单克隆抗体CAb—1轻、重链可变区基因及其应用 |
SE0303319D0 (sv) | 2003-12-10 | 2003-12-10 | Biacore Ab | Sample flow positioning method and analytical system using the method |
AU2005257705A1 (en) | 2004-06-24 | 2006-01-05 | Ge Healthcare Bio-Sciences Ab | Method for detecting molecular surface interactions |
SE0402476D0 (sv) | 2004-10-13 | 2004-10-13 | Biacore Ab | Preparation and use of a reactive solid support surface |
-
2006
- 2006-12-08 DO DO2006000277A patent/DOP2006000277A/es unknown
- 2006-12-12 CA CA002633038A patent/CA2633038A1/en not_active Abandoned
- 2006-12-12 NZ NZ569698A patent/NZ569698A/en not_active IP Right Cessation
- 2006-12-12 SG SG201102213-4A patent/SG170793A1/en unknown
- 2006-12-12 EP EP06847583.9A patent/EP1963372B1/en not_active Not-in-force
- 2006-12-12 RU RU2008128311/10A patent/RU2427590C2/ru not_active IP Right Cessation
- 2006-12-12 BR BRPI0619606-3A patent/BRPI0619606A2/pt not_active IP Right Cessation
- 2006-12-12 TW TW102102551A patent/TW201323443A/zh unknown
- 2006-12-12 WO PCT/US2006/047445 patent/WO2007070538A2/en active Application Filing
- 2006-12-12 KR KR1020087016992A patent/KR101551878B1/ko not_active IP Right Cessation
- 2006-12-12 AU AU2006326476A patent/AU2006326476A1/en not_active Abandoned
- 2006-12-12 JP JP2008545754A patent/JP2009519341A/ja active Pending
- 2006-12-12 CN CN201210041863.4A patent/CN102585001B/zh not_active Expired - Fee Related
- 2006-12-12 US US12/086,320 patent/US8168758B2/en not_active Expired - Fee Related
- 2006-12-12 EP EP12001060A patent/EP2476706A3/en not_active Withdrawn
- 2006-12-12 PE PE2006001590A patent/PE20071055A1/es not_active Application Discontinuation
- 2006-12-12 AR ARP060105473A patent/AR058325A1/es unknown
- 2006-12-12 ES ES06847583T patent/ES2428373T3/es active Active
- 2006-12-12 MX MX2008007502A patent/MX2008007502A/es active IP Right Grant
- 2006-12-12 TW TW095146346A patent/TWI392686B/zh active
- 2006-12-12 UY UY30006A patent/UY30006A1/es not_active Application Discontinuation
- 2006-12-12 CN CN200680052716XA patent/CN101501184B/zh not_active Expired - Fee Related
- 2006-12-12 PE PE2011000458A patent/PE20110797A1/es not_active Application Discontinuation
-
2008
- 2008-06-12 IL IL192129A patent/IL192129A0/en unknown
- 2008-06-12 EC EC2008008529A patent/ECSP088529A/es unknown
- 2008-06-12 GT GT200800098A patent/GT200800098A/es unknown
- 2008-06-12 TN TNP2008000255A patent/TNSN08255A1/en unknown
- 2008-06-12 CR CR10068A patent/CR10068A/es not_active Application Discontinuation
- 2008-06-16 HN HN2008000878A patent/HN2008000878A/es unknown
- 2008-07-01 ZA ZA200805741A patent/ZA200805741B/xx unknown
- 2008-07-11 MA MA31105A patent/MA30684B1/fr unknown
-
2009
- 2009-11-27 HK HK09111162.0A patent/HK1133441A1/xx not_active IP Right Cessation
-
2011
- 2011-06-29 RU RU2011126596/15A patent/RU2011126596A/ru not_active Application Discontinuation
-
2012
- 2012-04-30 US US13/459,558 patent/US20120301468A1/en not_active Abandoned
- 2012-06-08 JP JP2012130881A patent/JP2012211153A/ja active Pending
-
2013
- 2013-01-18 HK HK13100832.7A patent/HK1173734A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20071055A1 (es) | Anticuerpos anti mn | |
PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
EA201991099A1 (ru) | Антитела против cd73 и их применение | |
RS52484B (en) | CD40 ANTIBODIES | |
EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
RS53042B (en) | ANTIBODIES AGAINST ERBB3 AND THEIR USES | |
EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
RS54271B1 (en) | HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1) | |
PE20050712A1 (es) | Anticuerpos rg1 | |
CO6331370A2 (es) | Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos | |
PE20140218A1 (es) | Composicion farmaceutica | |
EA201291243A1 (ru) | Антитела против респираторно-синцитиального вируса (рсв) и способы их применения | |
NZ709390A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
MY194997A (en) | Anti-ccr7 antibody drug conjugates | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
RU2011121818A (ru) | Способ иммунологического анализа белка cxcl1 человека | |
EA201491851A1 (ru) | Композиции и способы для лечения болезни альцгеймера | |
RU2017113732A (ru) | Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |